DrugBiological
Peptide YY human (3-36) clinical trials
Also written PYY3-36.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2006
How studies write it
Studies that test it under each name
Development codes
Other names
Studies by the year they started
5 studies that test it; most in 2006 (1)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2011 | 1 |
| 2014 | 1 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 3
Gila Therapeutics, Inc. (1) · Hvidovre University Hospital (1) · University of Copenhagen (1) · University Hospital, Basel, Switzerland (1) · Nastech Pharmaceutical Company, Inc. (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses peptide YY human (3-36) is read from its arms, and is right about nine times in ten.
Testing it · 5
- A Dose Escalating Study to Assess the Safety and Tolerability of GT-001CompletedPhase 1Gila Therapeutics, Inc.NCT03490786Written as GT-001
- Degradation of the Anorexic Hormone Peptide YYCompletedEarly Phase 1Hvidovre University HospitalNCT02493959Written as PYY3-36 infusion
- Effects of Intravenous Infusions of Gut Hormones on Appetite and Metabolism.CompletedNot applicableUniversity of CopenhagenNCT00940134Written as PYY 3-36
- Oral Administration of Peptides; Absorption From Gastrointestinal TractCompletedPhase 1University Hospital, Basel, SwitzerlandNCT00468884Written as PYY3-36
- A Study of Nasal PYY3-36 and Placebo for Weight Loss in Obese SubjectsCompletedPhase 2Nastech Pharmaceutical Company, Inc.NCT00537420Written as PYY3-36